NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 124
(Total Views: 107)
Posted On: 06/26/2024 4:42:23 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed a patent with the U.S. Patent and Trademark Office. The patent covers novel solid forms of buntanetap, selecting the best crystal and building upon the provisional patent the company filed in June 2023. Formerly known as posiphen or ANVS401, buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins connected with disease, including amyloid beta, tau, alpha-synuclein and TDP43. Through this process, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s and other neurodegenerative diseases. The company has selected the most stable crystal form of buntanetap as the lead compound for animal bridge studies and for developing a manufacturing process. “The invention of a new solid form of our drug, buntanetap and the subsequent patent filing represent groundbreaking milestones for our company,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “This achievement will allow us not only to continue advancing our pipeline but also to enhance the drug’s properties, ultimately providing greater benefits to our patients.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed a patent with the U.S. Patent and Trademark Office. The patent covers novel solid forms of buntanetap, selecting the best crystal and building upon the provisional patent the company filed in June 2023. Formerly known as posiphen or ANVS401, buntanetap targets neurodegeneration by hindering the formation of multiple neurotoxic proteins connected with disease, including amyloid beta, tau, alpha-synuclein and TDP43. Through this process, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s and other neurodegenerative diseases. The company has selected the most stable crystal form of buntanetap as the lead compound for animal bridge studies and for developing a manufacturing process. “The invention of a new solid form of our drug, buntanetap and the subsequent patent filing represent groundbreaking milestones for our company,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “This achievement will allow us not only to continue advancing our pipeline but also to enhance the drug’s properties, ultimately providing greater benefits to our patients.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)